starling oncology inc - STLN

STLN

Close Chg Chg %
7.05 -0.35 -4.89%

Open Market

6.71

-0.35 (4.89%)

Volume: 732.43K

Last Updated:

Sep 23, 2026, 3:34 PM EDT

Company Overview: starling oncology inc - STLN

STLN Key Data

Open

$7.00

Day Range

6.61 - 7.00

52 Week Range

2.32 - 7.13

Market Cap

$682.88M

Shares Outstanding

99.98M

Public Float

63.57M

Beta

0.44

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.31

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.32M

 

STLN Performance

1 Week
 
1.29%
 
1 Month
 
9.05%
 
3 Months
 
30.80%
 
1 Year
 
99.15%
 
5 Years
 
-29.15%
 

STLN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About starling oncology inc - STLN

Starling Oncology, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.

STLN At a Glance

Starling Oncology, Inc.
18000 Studebaker Road
Cerritos, California 90703
Phone 1-562-735-3226 Revenue 502.73M
Industry Medical/Nursing Services Net Income -50,305,000.00
Sector Health Services 2025 Sales Growth 27.787%
Fiscal Year-end 12 / 2026 Employees 641
View SEC Filings

STLN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.654
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -13.696
Enterprise Value to Sales 0.794
Total Debt to Enterprise Value 0.26

STLN Efficiency

Revenue/Employee 784,288.612
Income Per Employee -78,478.939
Receivables Turnover 8.475
Total Asset Turnover 2.838

STLN Liquidity

Current Ratio 1.589
Quick Ratio 1.351
Cash Ratio 0.473

STLN Profitability

Gross Margin 13.823
Operating Margin -7.177
Pretax Margin -12.081
Net Margin -10.006
Return on Assets -28.395
Return on Equity N/A
Return on Total Capital -57.145
Return on Invested Capital -50.093

STLN Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 117.857
Total Debt to Total Assets 60.172
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 109.687
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Starling Oncology Inc - STLN

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
252.48M 324.24M 393.41M 502.73M
Sales Growth
+24.37% +28.42% +21.33% +27.79%
Cost of Goods Sold (COGS) incl D&A
204.80M 270.54M 345.70M 433.24M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.41M 5.87M 6.29M 6.94M
Depreciation
1.53M 2.86M 3.19M 3.96M
Amortization of Intangibles
2.88M 3.01M 3.10M 2.98M
COGS Growth
+23.75% +32.10% +27.78% +25.32%
Gross Income
47.68M 53.70M 47.71M 69.49M
Gross Income Growth
+27.13% +12.62% -11.15% +45.65%
Gross Profit Margin
+18.89% +16.56% +12.13% +13.82%
2022 2023 2024 2025 5-year trend
SG&A Expense
118.90M 113.74M 107.83M 105.57M
Research & Development
- - - -
-
Other SG&A
118.90M 113.74M 107.83M 105.57M
SGA Growth
+42.62% -4.34% -5.20% -2.09%
Other Operating Expense
- - - -
-
Unusual Expense
(74.71M) 15.59M (3.32M) 12.45M
EBIT after Unusual Expense
3.49M (75.62M) (56.80M) (48.54M)
Non Operating Income/Expense
501.00K (704.00K) (365.00K) (925.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.08M 6.78M 7.50M 11.28M
Interest Expense Growth
+1,175.63% +66.02% +10.61% +50.43%
Gross Interest Expense
4.08M 6.78M 7.50M 11.28M
Interest Capitalized
- - - -
-
Pretax Income
(91.00K) (83.10M) (64.66M) (60.74M)
Pretax Income Growth
+99.22% -91,223.08% +22.19% +6.07%
Pretax Margin
-0.04% -25.63% -16.44% -12.08%
Income Tax
- (243.00K) (36.00K) (131.00K)
Income Tax - Current - Domestic
- - 40.00K (99.00K)
-
Income Tax - Current - Foreign
- - - 20.00K
-
Income Tax - Deferred - Domestic
- (263.00K) (76.00K) (32.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
(20.00K) 15.19M 11.66M 10.30M
Consolidated Net Income
132.00K (67.88M) (53.01M) (50.30M)
Minority Interest Expense
- - - -
-
Net Income
132.00K (67.88M) (53.01M) (50.30M)
Net Income Growth
+101.21% -51,521.97% +21.91% +5.09%
Net Margin Growth
+0.05% -20.93% -13.47% -10.01%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
132.00K (67.88M) (53.01M) (50.30M)
Preferred Dividends
- - - 64.00K
-
Net Income Available to Common
68.00K (67.88M) (53.01M) (50.30M)
EPS (Basic)
0.0009 -0.9204 -0.7063 -0.5445
EPS (Basic) Growth
+100.55% -102,366.67% +23.26% +22.91%
Basic Shares Outstanding
72.79M 73.75M 75.04M 92.39M
EPS (Diluted)
-0.2107 -0.9204 -0.7063 -0.5445
EPS (Diluted) Growth
-27.70% -336.83% +23.26% +22.91%
Diluted Shares Outstanding
80.61M 73.75M 75.04M 92.39M
EBITDA
(66.81M) (54.16M) (53.83M) (29.14M)
EBITDA Growth
-57.13% +18.92% +0.61% +45.87%
EBITDA Margin
-26.46% -16.70% -13.68% -5.80%

Snapshot

Average Recommendation BUY Average Target Price 9.25
Number of Ratings 4 Current Quarters Estimate -0.05
FY Report Date 09 / 2026 Current Year's Estimate -0.163
Last Quarter’s Earnings -0.08 Median PE on CY Estimate N/A
Year Ago Earnings -0.54 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate -0.05 -0.01 -0.16 0.00
High Estimates -0.04 0.03 -0.11 0.10
Low Estimate -0.07 -0.04 -0.21 -0.06
Coefficient of Variance -28.28 -398.15 -26.29 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Starling Oncology Inc in the News